TRADES
Latest Trades
70
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 23 Feb 2022 Sell IONS IONIS PHARMACEUTICALS INC 330,291 0.2920
ARKG 22 Feb 2022 Sell IONS IONIS PHARMACEUTICALS INC 353,306 0.3076
ARKG 10 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 34,500 0.0277
ARKG 8 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 12,026 0.0097
ARKG 7 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 2,850 0.0023
ARKG 4 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 8,173 0.0065
ARKG 2 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 596 0.0004
ARKG 1 Feb 2022 Buy IONS IONIS PHARMACEUTICALS INC 6,208 0.0047
ARKG 31 Jan 2022 Buy IONS IONIS PHARMACEUTICALS INC 286,000 0.2370
ARKG 10 Jan 2022 Sell IONS IONIS PHARMACEUTICALS INC 326,031 0.2190
ARKG 23 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 35,468 0.0210
ARKG 22 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 530 0.0003
ARKG 21 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 152,043 0.0924
ARKG 20 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 61,200 0.0364
ARKG 27 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 88,993 0.0386
ARKG 26 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 182,409 0.0773
ARKG 23 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 58,244 0.0247
ARKG 22 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 14,067 0.0058
ARKG 21 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 65,060 0.0269
ARKG 20 Jul 2021 Buy IONS IONIS PHARMACEUTICALS INC 54,702 0.0232
ARKG 29 Jun 2021 Buy IONS IONIS PHARMACEUTICALS INC 268,748 0.1112
ARKG 28 Jun 2021 Buy IONS IONIS PHARMACEUTICALS INC 325,571 0.1366
ARKG 25 Jun 2021 Buy IONS IONIS PHARMACEUTICALS INC 112,462 0.0473
ARKG 17 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 36,648 0.0181
ARKG 14 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 159,649 0.0787
ARKG 13 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 158,025 0.0777
ARKG 12 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 130,900 0.0617
ARKG 11 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 108,046 0.0497
ARKG 10 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 134,100 0.0605
ARKG 7 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 333,215 0.1467
ARKG 6 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 361,351 0.1568
ARKG 5 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 128,664 0.0632
ARKG 4 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 482,340 0.2281
ARKG 3 May 2021 Buy IONS IONIS PHARMACEUTICALS INC 308,896 0.1417
ARKG 30 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 84,878 0.0379
ARKG 29 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 128,124 0.0572
ARKG 28 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 29,941 0.0131
ARKG 27 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 161,563 0.0706
ARKG 26 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 76,959 0.0334
ARKG 23 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 78,639 0.0346
ARKG 22 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 18,496 0.0081
ARKG 21 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 108,698 0.0467
ARKG 20 Apr 2021 Buy IONS IONIS PHARMACEUTICALS INC 90,284 0.0391
ARKG 24 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 310,023 0.1489
ARKG 23 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 584,838 0.2705
ARKG 22 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 46,225 0.0254
ARKG 17 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 90,493 0.0481
ARKG 16 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 214,492 0.1168
ARKG 15 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 12,557 0.0067
ARKG 12 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 79,806 0.0432
ARKG 11 Mar 2021 Buy IONS IONIS PHARMACEUTICALS INC 55,889 0.0298
ARKG 29 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 67,820 0.0400
ARKG 28 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 28,000 0.0200
ARKG 27 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 91,851 0.0518
ARKG 26 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 134,100 0.0761
ARKG 25 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 176,756 0.0952
ARKG 22 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 77,059 0.0415
ARKG 21 Jan 2021 Buy IONS IONIS PHARMACEUTICALS INC 53,044 0.0290
ARKG 29 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 12,707 0.0099
ARKG 28 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 201,100 0.1566
ARKG 24 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 24,779 0.0191
ARKG 21 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 49,817 0.0407
ARKG 18 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 45,550 0.0391
ARKG 17 Dec 2020 Buy IONS IONIS PHARMACEUTICALS INC 152,185 0.1265
ARKG 21 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 43,644 0.0716
ARKG 20 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 44,012 0.0696
ARKG 19 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 25,277 0.0393
ARKG 14 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 62,339 0.1016
ARKG 13 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 89,700 0.1437
ARKG 12 Oct 2020 Buy IONS IONIS PHARMACEUTICALS INC 72,902 0.1200
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.